JORVEZA Oral suspension Ref.[116525] Active ingredients: Budesonide

Source: European Medicines Agency (EU)  Revision Year: 2026  Publisher: Dr. Falk Pharma GmbH, Leinenweberstr. 5, 79108 Freiburg, Germany, Tel.: +49 (0)761 1514-0, Fax: +49 (0)761 1514-321, E-mail: zentrale@drfalkpharma.de

Product name and form

Jorveza 0.2 mg/mL oral suspension.

Pharmaceutical Form

Oral suspension.

Whitish, viscous suspension.

Qualitative and quantitative composition

Each mL of oral suspension contains 0.2 mg budesonide.

Each bottle of 165 mL contains 33 mg budesonide.

Excipients with known effect:

Each mL of oral suspension contains 100 mg sucrose and 0.86 mg sodium benzoate (E211).

For the full list of excipients, see section 6.1.

Active Ingredient

Budesonide is a glucocorticosteroid with a high local anti-inflammatory effect. At doses clinically equivalent to systemically acting glucocorticosteroids, budesonide gives significantly less HPA axis suppression and has a lower impact on inflammatory markers.

List of Excipients

Sucrose
Water, purified
Sodium benzoate (E211)
Disodium edetate
Citric acid
Methylcellulose [1500 mPas]
Blackcurrant flavour

Pack sizes and marketing

200 mL amber glass bottle of blow moulded type III glass.

Child-resistant closure:

White ribbed cap (PP) with a colourless screw closure (HDPE) and an internal colourless flow limiter (LDPE). After first opening, the flow limiter remains in the bottle neck and enables the insertion of the oral syringe to draw the suspension.

Syringe for oral administration:

CE-certified oral syringe consisting of a colourless barrel (PP) with a colourless screw closure (HDPE) and graduations for 2.5 mL and 5 mL, and a white plunger (HDPE).

Pack size:

One bottle containing 165 mL of oral suspension with one graduated oral syringe for oral administration.

Marketing authorization holder

Dr. Falk Pharma GmbH, Leinenweberstr. 5, 79108 Freiburg, Germany, Tel.: +49 (0)761 1514-0, Fax: +49 (0)761 1514-321, E-mail: zentrale@drfalkpharma.de

Marketing authorization dates and numbers

EU/1/17/1254/012

Date of first authorisation: 08 January 2018
Date of latest renewal: 27 September 2022

Drugs

Drug Countries
JORVEZA Austria, Canada, Estonia, Spain, Finland, France, Croatia, Ireland, Israel, Italy, Lithuania, Netherlands, New Zealand, Poland, United Kingdom

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.